Zoetis said total revenue for the quarter ended June 30, 2024 rose $181 million (8%) from a year earlier, and rose $243 million (11%) on an operational basis, which excludes the impact of foreign exchange.

1. 01

   Zoetis said total revenue for the quarter ended June 30, 2024 rose $181 million (8%) from a year earlier, and rose $243 million (11%) on an operational basis, which excludes the impact of foreign exchange.

2. 02

   The company said its total revenue for the 6 months ended June 30, 2024 rose $371 million (9%) from a year earlier, and that on an operational basis it rose $482 million (12%). It also said that the year-over-year total revenue growth was not a comparison with the prior full year, but that foreign currency changes unfavorably affected year-over-year total revenue growth by about 3%.

3. 03

   Zoetis said its cost of sales as a percentage of revenue was 28.3% in Q2 2024, up from 27.8% a year earlier. It added that SG&A expenses rose $25 million (4%) and R&D expenses rose $25 million (17%).

4. 04

   The company said it repurchased 5.0 million shares for $872 million in the first half of 2024. It said $623 million remained of the $3.5 billion authorized program as of June 30. Net cash used in financing activities for the 6 months was $1,287 million.

Key figures

Quarter ended June 30, 2024

Revenue

$2.4B

Net income

$624M

EPS

$1.37

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.